Role of gut microbiota in the treatment of nonalcoholic fatty liver disease with traditional Chinese medicine
10.16438/j.0513-4870.2019-0614
- VernacularTitle:肠道微生物群在中药治疗非酒精性脂肪性肝病中的作用
- Author:
Xiao-lin LI
1
;
Wei JIANG
2
;
Wei-ming FAN
2
;
Xiao-feng FU
2
;
Lu-lu WANG
1
;
Jian-dong JIANG
1
Author Information
1. Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. Institute of Zhejiang Zhenyuan Pharmaceutical Corporation, Shaoxing 312000, China
- Publication Type:Research Article
- Keywords:
gut microbiota;
nonalcoholic fatty liver disease;
mechanism;
traditional Chinese medicine
- From:
Acta Pharmaceutica Sinica
2020;55(1):15-24
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is a genetic and environmental factor-associated metabolic disease that can lead to fibrosis, cirrhosis and hepatocellular carcinoma. In recent decades the prevalence of NAFLD has increased, but effective pharmacotherapy is limited. Treatment regimens in traditional Chinese medicine (TCM) have made significant contributions to the control of NAFLD, but underlying mechanisms are far less elucidated. Increasing evidence suggests that gut microbiota play a crucial role in the pathogenesis and development of diseases including NAFLD. The outcomes of such research open a new approach in identifying the molecular mechanisms of TCM. Here we review the evidence that gut microbiota might be a target in the treatment NAFLD using TCM.
